Core Insights - AB Science provided an update on its masitinib platform, highlighting its potential in treating various neurological diseases, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease [1][5]. Group 1: Masitinib Platform Developments - A new confirmatory study (AB23005) will be initiated, simplifying enrollment and targeting the best responders for masitinib, in line with recommendations from the FDA and EMA [5]. - The design of the study has been validated and authorized by both the FDA and EMA, securing a pathway to registration with these agencies [5]. - The first study (AB10015) generated strong hypotheses regarding patient survival, showing a significant +12 months survival benefit and a long-term follow-up indicating that 53% of patients survived more than 5 years, with a +36 months benefit over ENCLALS predictions [5]. Group 2: Mechanism of Action and Efficacy - Masitinib's mechanism of action targets microglia and mast cells, which are crucial in the innate immune response, enhancing its efficacy in treating neurological diseases [5]. - The drug has shown competitive results compared to BTK inhibitors in terms of EDSS progression, despite the populations being non-comparable [5]. - Masitinib is the only drug that has generated positive results in moderate Alzheimer's disease and could potentially be combined with biologics for early and mild cases [5]. Group 3: Market Potential and Intellectual Property - The unmet medical need in ALS, MS, and Alzheimer's disease is immense, with potential sales exceeding billions in each indication [5]. - Masitinib's intellectual property rights are secured through a use patent until 2037 in ALS and up to 2041 in MS and Alzheimer's, along with orphan drug status in ALS and data protection of 10 years in Europe and 8 years in the USA [5]. Group 4: Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [6][7]. - The company is headquartered in Paris, France, and is listed on Euronext Paris [7].

Core Viewpoint - AB Science will host a live webcast on January 28, 2025, to provide updates on its masitinib platform [1][2] Company Overview - AB Science is a pharmaceutical company founded in 2001, focusing on the research, development, and commercialization of protein kinase inhibitors (PKIs) [1][2] - The company targets diseases with high unmet medical needs, including oncology, neurological diseases, inflammatory diseases, and viral diseases [2] Product Development - The lead compound, masitinib, is already registered for veterinary medicine and is being developed for human medicine [2] - The company emphasizes its commitment to addressing diseases that are often lethal or refractory to previous treatments [2]

Core Viewpoint - AllianceBernstein L.P. and AllianceBernstein Holding L.P. will release their Fourth Quarter 2024 financial and operating results on February 6, 2025, before market opening [1] Group 1: Financial Results Announcement - The financial results will be discussed in a teleconference starting at 10:00 am (CT) on the same day [1] - The call will be hosted by key executives including Seth Bernstein, Jackie Marks, and Onur Erzan [1] Group 2: Accessing the Conference Call - Parties can access the conference call via webcast or telephone, with a presentation available on the Investor Relations website shortly after the results release [2] - A replay of the webcast will be available approximately one hour after the call [2] Group 3: Company Overview - AllianceBernstein is a leading global investment management firm providing diversified investment services to institutional investors, individuals, and private wealth clients [3] - As of December 31, 2024, AllianceBernstein Holding owned approximately 37.5% of AllianceBernstein, while Equitable Holdings, Inc. owned about 61.9% economic interest in the firm [4]

Company Overview - AB Science is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) [2] - The company targets diseases with high unmet medical needs, including those that are often lethal or rare and refractory to previous treatments [2] Product Development - AB Science has developed a proprietary portfolio of molecules, with its lead compound, masitinib, already registered for veterinary medicine and under development for human medicine in various fields such as oncology, neurological diseases, inflammatory diseases, and viral diseases [3] Upcoming Events - AB Science's management team will participate in the Biomed Forum, a conference for institutional investors, scheduled for February 4, 2025, in Paris [1]

Disclosure - The analyst has no stock, option, or derivative positions in any mentioned companies and no plans to initiate such positions within the next 72 hours [1] - The article expresses the analyst's own opinions and is not receiving compensation other than from Seeking Alpha [1] - The analyst has no business relationship with any company whose stock is mentioned in the article [1] - Seeking Alpha's disclosure states that past performance is no guarantee of future results and no investment recommendations are being given [2] - Seeking Alpha is not a licensed securities dealer, broker, or US investment adviser, and its analysts may not be licensed or certified by any regulatory body [2]

Core Insights - AllianceBernstein L.P. and AllianceBernstein Holding L.P. reported a decrease in preliminary assets under management (AUM) to $792 billion in December 2024, down from $813 billion at the end of November 2024, representing a 2.6% decline [1] - The decline in AUM was attributed to market depreciation and net outflows across all three channels: Institutions, Retail, and Private Wealth, with total net outflows for the quarter ending December 2024 amounting to $5.0 billion [1] AUM Breakdown - As of December 31, 2024, the total AUM was composed of: - Institutions: $321 billion - Retail: $334 billion - Private Wealth: $137 billion - Total AUM: $792 billion [3] - The previous month (November 30, 2024) showed a total AUM of $813 billion, with the breakdown as follows: - Institutions: $331 billion - Retail: $342 billion - Private Wealth: $140 billion [3] Investment Strategy - The AUM includes various investment strategies: - Total Equity: $332 billion (down from $343 billion) - Total Fixed Income: $296 billion (down from $303 billion) - Alternatives/Multi-Asset: $164 billion (down from $167 billion) [3]

Core Viewpoint - AB Science provides an update on its AB8939 program, a novel microtubule destabilizer and ALDH inhibitor, currently in Phase 1 trials for treating acute myeloid leukemia (AML) [2]. Group 1: Product Profile and Mechanism - AB8939 is a next-generation synthetic microtubule destabilizer and stem cell-targeted ALDH1/2 inhibitor, designed for refractory/relapsing AML treatment [3]. - The drug destabilizes microtubules and is not affected by multidrug resistance mechanisms, as it does not bind to PgP and is not degraded by myeloperoxidase [4]. - AB8939 inhibits ALDH1/2, promoting the repopulation of normal progenitors in the bone marrow [5]. Group 2: Clinical Efficacy and Market Potential - AB8939 demonstrates activity across refractory AML cell lines and shows an additive effect when combined with first-line treatments like cytarabine, azacitidine, and venetoclax [6]. - The drug has potential efficacy in AML with MECOM gene rearrangement, a patient subset known for extreme resistance to chemotherapy and poor survival prognosis [7]. - The addressable market for AB8939 in relapsed/refractory AML is estimated to exceed EUR 2 billion annually [7]. Group 3: Market Size Data - In the USA and Canada, there are approximately 23,700 incidence cases of AML, with a 50% relapse or refractory rate, leading to a market size of EUR 1 billion [8]. - Europe has around 27,600 incidence cases, with a market size of EUR 770 million [8]. - The Asia-Pacific region reports 27,800 incidence cases, with a market size of EUR 250 million [8]. Group 4: Clinical Development and Intellectual Property - The Phase 1 trial aims to determine the maximum tolerated dose (MTD) of AB8939, with 28 patients enrolled in the first step and 10 in the second step [11]. - Future steps include evaluating the MTD after 14 consecutive days of treatment in combination with venetoclax or azacitidine [12]. - AB8939's intellectual property rights in AML are secured until 2036, with potential extension until 2044 for specific chromosome abnormalities [18].

Core Insights - AllianceBernstein L.P. and AllianceBernstein Holding L.P. reported a preliminary increase in assets under management (AUM) to $813 billion in November 2024, up from $793 billion at the end of October, representing a 2.5% month-over-month growth driven by market appreciation, despite net outflows [1][2]. AUM Breakdown - Total AUM as of November 30, 2024, includes: - Total Equity: $343 billion, up from $333 billion in October, with actively managed equity at $272 billion and passive equity at $71 billion [2]. - Total Fixed Income: $303 billion, an increase from $296 billion in October, with taxable fixed income at $215 billion and tax-exempt fixed income at $77 billion [2]. - Alternatives/Multi-Asset Solutions: $167 billion, up from $164 billion in October [2]. - By channel, net inflows in Retail and Private Wealth were outweighed by Institutional net outflows [1].

Group 1 - AllianceBernstein L.P. and AllianceBernstein Holding L.P. announced that Seth Bernstein, President and CEO, will participate in the Goldman Sachs 2024 US Financial Services Conference on December 10, 2024 [1] - A live audio webcast of the conference will be available on AB's website, with a replay accessible shortly after the event [2] - AllianceBernstein is a leading global investment management firm providing high-quality research and diversified investment services to various clients [3] Group 2 - As of September 30, 2024, AllianceBernstein Holding owned approximately 39.3% of AllianceBernstein, while Equitable Holdings, Inc. owned an approximate 61.6% economic interest in the firm [4]

Group 1 - Investment operations may involve the use of specific portfolio management techniques, including credit [1]